EUVIMEDEUVIMED entdecken
Crossref

Integrative Metabolomics and Molecular Docking as a Drug Discovery Approach: A Case Study of Microbial Cyclo(Gly-L-Pro) Targeting Alzheimer’s Disease

Dan Tang iD, Jie Luo, Zi-Ming He, Hao-Lin Qian, Xiao-Xia Zhou, Yong-Gang Wang

Planta Medica · 21.10.2026

DOI: 10.1055/a-2978-1740 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Planta Medica, erschienen am 21.10.2026. Verfasst von Dan Tang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Lanzhou University of Technology, School of Life Science and Engineering, Gansu, China, Lanzhou. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Innovation Projects for Young Scientific and Technological Talents in Lanzhou City, Gansu Province, Science and Technology Program of Gansu Province, National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The urgent need for effective Alzheimer’s disease (AD) therapies has spurred the search for novel bioactive compounds within the vast chemical space of microbial natural products. Here, we integrated nontargeted metabolomics with network pharmacology to explore the neuroprotective potential of Streptomyces flavusporus HC307. Systematic profiling of the HC307 metabolome revealed nearly 3000 features. Subsequent statistical screening and database matching narrowed the focus to 34 potential anti-AD candidates, facilitating the targeted isolation of the bioactive cyclodipeptide, cyclo(Gly-L-Pro) (307-1). Network pharmacology analysis predicted that cyclo(Gly-L-Pro) may modulate a network of 86 AD-related targets, with EGFR, CTSB, GSK3B, PARP1, and SIRT1 serving as core nodes. Molecular docking showed favorable binding affinities, particularly toward GSK3B and PARP1 (−6.6 kcal mol−1 for both), suggesting a multifaceted mechanism spanning tau protein regulation, anti-inflammation, and oxidative stress mitigation. This study establishes S. flavusporus HC307 as a promising source of neuroactive leads and elucidates the multitarget profile of cyclo(Gly-L-Pro), providing a basis for its further development as an anti-AD lead.

Autor:innen und Institutionen

  • Lanzhou University of Technology, School of Life Science and Engineering, Gansu, China, Lanzhou.

ORCID-Profile: Dan Tang

Förderung

  • Innovation Projects for Young Scientific and Technological Talents in Lanzhou City, Gansu Province
  • Science and Technology Program of Gansu Province
  • National Natural Science Foundation of China
  • Lanzhou University of Technology

Zitieren

APA

Tang, D., Luo, J., He, Z. M., Qian, H. L., Zhou, X. X., & Wang, Y. G. (2026). Integrative Metabolomics and Molecular Docking as a Drug Discovery Approach: A Case Study of Microbial Cyclo(Gly-L-Pro) Targeting Alzheimer’s Disease. Planta Medica. https://doi.org/10.1055/a-2978-1740

Vancouver

Tang D, Luo J, He ZM, Qian HL, Zhou XX, Wang YG. Integrative Metabolomics and Molecular Docking as a Drug Discovery Approach: A Case Study of Microbial Cyclo(Gly-L-Pro) Targeting Alzheimer’s Disease. Planta Medica. 2026. doi:10.1055/a-2978-1740

BibTeX
@article{Tang2026,
  author = {Tang, Dan and Luo, Jie and He, Zi-Ming and Qian, Hao-Lin and Zhou, Xiao-Xia and Wang, Yong-Gang},
  title = {Integrative Metabolomics and Molecular Docking as a Drug Discovery Approach: A Case Study of Microbial Cyclo(Gly-L-Pro) Targeting Alzheimer’s Disease},
  journal = {Planta Medica},
  year = {2026},
  doi = {10.1055/a-2978-1740}
}
Kostenlos starten →